CA-125: what your result means.

A protein marker used primarily for ovarian cancer screening in women. CA-125 is measured by blood test as part of the CatastrophicScreen panel in the HodieLabs Health Blueprint.

Note: this biomarker is measured and interpreted for females; reference ranges are sex-specific.

Note: this is an optional biomarker in the HodieLabs panel, included based on individual risk profile and preference after doctor discussion.

Why CA-125 matters

GOVERNANCE: USPSTF recommends against screening asymptomatic average-risk women for ovarian cancer with CA-125 or ultrasound because it does not reduce mortality and causes false positives and unnecessary surgery. CA-125 should be restricted to symptom-driven evaluation or defined hereditary/high-risk pathways (e.g. BRCA1/2 carriers), not offered as a routine optional wellness screen for average-risk users.

Associated risks when out of range: Elevated in ovarian cancer but also endometriosis, PID, liver disease, and peritoneal inflammation. Poor specificity as a standalone screening tool, best used for monitoring known ovarian cancer.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets CA-125, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• UKCTOCS trial (Jacobs et al. The Lancet 2016): the largest ovarian cancer screening trial (~200,000 women) found CA-125-based screening detected cancers earlier but did not clearly reduce mortality. Why CA-125 is used for targeted investigation rather than population screening.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets CA-125 against published clinical authority standards, never arbitrary "optimal" ranges. Measured in U/mL:

Band	Range (U/mL)
Optimal	<35 U/mL
Borderline	35–65 U/mL
High	>65 U/mL

Clinical interpretation

• GOVERNANCE: USPSTF recommends against screening asymptomatic average-risk women for ovarian cancer with CA-125 or ultrasound because it does not reduce mortality and causes false positives and unnecessary surgery.
• CA-125 should be restricted to symptom-driven evaluation or defined hereditary/high-risk pathways (e.g. BRCA1/2 carriers), not offered as a routine optional wellness screen for average-risk users.
• Elevated in many benign conditions: endometriosis, PID, liver disease, peritoneal inflammation, menstruation.
• Serial trending is more useful than a single measurement when used in appropriate clinical contexts.
• Optional; non-specific; interpret with symptoms, family history, and clinical pathway.

What improves it: the evidence-based levers

• Interpret in clinical context. CA-125 alone should not trigger cancer investigation in low-risk women
• Serial trending is more useful than a single measurement

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How CA-125 testing works at HodieLabs

CA-125 is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Jacobs IJ, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–956.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.